The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
BET inhibitors: a novel epigenetic approach
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,662
Bird, A. (2007) · Nature · doi:10.1038/nature05913 · Cited by 3,011
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
The history of cancer epigenetics
Feinberg, A. P., & Tycko, B. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1279 · Cited by 2,344
Cancer epigenomics: DNA methylomes and histone-modification maps
Esteller, M. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2005 · Cited by 2,146
An operational definition of epigenetics: Figure 1.
Berger, S. L., Kouzarides, T., Shiekhattar, R., & Shilatifard, A. (2009) · Genes & Development · doi:10.1101/gad.1787609 · Cited by 1,884
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D., Powell, B. L., DeCastro, C. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.117 · Cited by 1,825
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Kantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. (2006) · Cancer · doi:10.1002/cncr.21792 · Cited by 1,530
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-W., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,503
Jang, M. K., Mochizuki, K., Zhou, M., Jeong, H.-S., Brady, J. N., & Ozato, K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.027 · Cited by 1,291
Targeting bromodomains: epigenetic readers of lysine acetylation
Filippakopoulos, P., & Knapp, S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4286 · Cited by 1,243
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
Recruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4
Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.029 · Cited by 1,138
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Mertz, J. A., Conery, A. R., Bryant, B. M., Sandy, P., Balasubramanian, S., Mele, D. A., Bergeron, L., & Sims, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108190108 · Cited by 1,110
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,055
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., Escara-Wilke, J., Wilder-Romans, K., Dhanireddy, S., Engelke, C., et al. (2014) · Nature · doi:10.1038/nature13229 · Cited by 927
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Shi, J., & Vakoc, C. R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.016 · Cited by 878
Pott, S., & Lieb, J. D. (2015) · Nature Genetics · doi:10.1038/ng.3167 · Cited by 761
Chapuy, B., McKeown, M. R., Lin, C. Y., Monti, S., Roemer, M. G. M., Qi, J., Rahl, P. B., Sun, H. H., Yeda, K. T., Doench, J. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.003 · Cited by 735
BET domain co-regulators in obesity, inflammation and cancer
Belkina, A. C., & Denis, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3256 · Cited by 711
The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis
Dey, A., Chitsaz, F., Abbasi, A., Misteli, T., & Ozato, K. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1433065100 · Cited by 669
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0418 · Cited by 637
The Myc oncoprotein as a therapeutic target for human cancer
Vita, M., & Henriksson, M. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.015 · Cited by 552
Rahman, S., Sowa, M. E., Ottinger, M., Smith, J. A., Shi, Y., Harper, J. W., & Howley, P. M. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01341-10 · Cited by 532
BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.
French, C. A., Miyoshi, I., Kubonishi, I., Grier, H. E., Pérez‐Atayde, A. R., & Fletcher, J. A. (2003) · PubMed · Cited by 501
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
Zhu, H., Bengsch, F., Svoronos, N., Rutkowski, M. R., Bitler, B. G., Allegrezza, M. J., Yokoyama, Y., Kossenkov, A. V., Bradner, J. E., Conejo-Garcia, J. R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.032 · Cited by 432
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Berthon, C., Raffoux, E., Thomas, X., Vey, N., Gomez-Roca, C., Yee, K., Taussig, D. C., Rezai, K., Roumier, C., Herait, P., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00247-1 · Cited by 420
Amorim, S., Stathis, A., Gleeson, M., Iyengar, S., Magarotto, V., Leleu, X., Morschhauser, F., Karlin, L., Broussais, F., Rezai, K., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00021-1 · Cited by 417
Stathis, A., Zucca, E., Bekradda, M., Gomez-Roca, C., Delord, J.-P., de La Motte Rouge, T., Uro-Coste, E., de Braud, F., Pelosi, G., & French, C. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1335 · Cited by 378
The Double Bromodomain Proteins Brd2 and Brd3 Couple Histone Acetylation to Transcription
LeRoy, G., Rickards, B., & Flint, S. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.01.018 · Cited by 372
BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin
Devaiah, B. N., Case-Borden, C., Gegonne, A., Hsu, C. H., Chen, Q., Meerzaman, D., Dey, A., Ozato, K., & Singer, D. S. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3228 · Cited by 361
Yang, Z., He, N., & Zhou, Q. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01020-07 · Cited by 347
Brd4 Marks Select Genes on Mitotic Chromatin and Directs Postmitotic Transcription
Dey, A., Nishiyama, A., Karpova, T., McNally, J., & Ozato, K. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-05-0380 · Cited by 316
Jiang, Y. W., Veschambre, P., Erdjument-Bromage, H., Tempst, P., Conaway, J. W., Conaway, R. C., & Kornberg, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8538 · Cited by 305
Boi, M., Gaudio, E., Bonetti, P., Kwee, I., Bernasconi, E., Tarantelli, C., Rinaldi, A., Testoni, M., Cascione, L., Ponzoni, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1561 · Cited by 284
BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
Coudé, M.-M., Braun, T., Berrou, J., Dupont, M., Bertrand, S., Masse, A., Raffoux, E., Itzykson, R., Delord, M., Riveiro, M. E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4131 · Cited by 274
PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains
Picaud, S., Da Costa, D., Thanasopoulou, A., Filippakopoulos, P., Fish, P. V., Philpott, M., Fedorov, O., Brennan, P., Bunnage, M. E., Owen, D. R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3292 · Cited by 249
Kummar, S., Chen, H. X., Wright, J., Holbeck, S., Millin, M. D., Tomaszewski, J., Zweibel, J., Collins, J., & Doroshow, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3216 · Cited by 247
BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
Segura, M. F., Fontanals-Cirera, B., Gaziel-Sovran, A., Guijarro, M. V., Hanniford, D., Zhang, G., González-Gomez, P., Morante, M., Jubierre, L., Zhang, W., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0122-t · Cited by 239
The Bromodomain Protein Brd4 Stimulates G1 Gene Transcription and Promotes Progression to S Phase
Mochizuki, K., Nishiyama, A., Jang, M. K., Dey, A., Ghosh, A., Tamura, T., Natsume, H., Yao, H., & Ozato, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707603200 · Cited by 229
Bhadury, J., Nilsson, L. M., Veppil Muralidharan, S., Green, L. C., Li, Z., Gesner, E. M., Hansen, H. C., Keller, U. B., McLure, K. G., & Nilsson, J. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406722111 · Cited by 212
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
Chaidos, A., Caputo, V., Gouvedenou, K., Liu, B., Marigo, I., Chaudhry, M. S., Rotolo, A., Tough, D. F., Smithers, N. N., Bassil, A. K., et al. (2014) · Blood · doi:10.1182/blood-2013-01-478420 · Cited by 203
An epigenomic approach to therapy for tamoxifen-resistant breast cancer
Feng, Q., Zhang, Z., Shea, M. J., Creighton, C. J., Coarfa, C., Hilsenbeck, S. G., Lanz, R., He, B., Wang, L., Fu, X., et al. (2014) · Cell Research · doi:10.1038/cr.2014.71 · Cited by 194
Fiskus, W., Sharma, S., Qi, J., Valenta, J. A., Schaub, L. J., Shah, B., Peth, K., Portier, B. P., Rodriguez, M., Devaraj, S. G. T., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0770 · Cited by 190
Iacobuzio-Donahue, C. A. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.151442 · Cited by 188
Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Henssen, A., Althoff, K., Odersky, A., Beckers, A., Koche, R., Speleman, F., Schäfers, S., Bell, E., Nortmeyer, M., Westermann, F., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1449 · Cited by 183
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
Wyce, A., Degenhardt, Y., Bai, Y., Le, B., Korenchuk, S., Crouthamel, M.-C., McHugh, C. F., Vessella, R., Creasy, C. L., Tummino, P. J., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1572 · Cited by 179
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
Henssen, A. G., Thor, T., Odersky, A., Heukamp, L. C., Hindy, N. E., Beckers, A., Speleman, F., Althoff, K., Schäfers, S., Schramm, A. R., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1534 · Cited by 165
Histone deacetylase inhibitors in hematological malignancies and solid tumors
Chun, P. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0571-1 · Cited by 158
RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F.
Denis, G. V., Vaziri, C., Guo, N., & Faller, D. V. (2000) · PubMed · Cited by 156
Denis, G. V., McComb, M. E., Faller, D. V., Sinha, A., Romesser, P. B., & Costello, C. E. (2006) · Journal of Proteome Research · doi:10.1021/pr050430u · Cited by 144
Shahbazi, J., Liu, P. Y., Atmadibrata, B., Bradner, J. E., Marshall, G. M., Lock, R. B., & Liu, T. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1666 · Cited by 124
Targeting the histone orthography of cancer: drugs for writers, erasers and readers
Simó‐Riudalbas, L., & Esteller, M. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12844 · Cited by 122
Ramakrishnan, G., Matta, H., Tolani, B., Triche, T. J., & Chaudhary, P. M. (2015) · Oncogene · doi:10.1038/onc.2015.245 · Cited by 116
Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A
Sinha, A., Faller, D. V., & Denis, G. V. (2005) · Biochemical Journal · doi:10.1042/bj20041793 · Cited by 116
Synergistic effect of JQ 1 and rapamycin for treatment of human osteosarcoma
Lee, D. H., Qi, J., Bradner, J. E., SAID, J. W., Doan, N., Forscher, C. A., Yang, H. H., & Koeffler, H. P. (2014) · International Journal of Cancer · doi:10.1002/ijc.29269 · Cited by 112
Two faces of BRD4: Mitotic bookmark and transcriptional lynchpin
Devaiah, B. N., & Singer, D. S. (2013) · Transcription · doi:10.4161/trns.22542 · Cited by 97
Jostes, S., Nettersheim, D., Fellermeyer, M., Schneider, S., Hafezi, F., Honecker, F. U., Schumacher, V., Geyer, M., Kristiansen, G., & Schorle, H. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13059 · Cited by 91
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
Bolin, S., Borgenvik, A., Persson, C., Sundström, A., Qi, J., Bradner, J. E., Weiss, W. A., Cho, Y., Weishaupt, H., & Swartling, F. J. (2018) · Oncogene · doi:10.1038/s41388-018-0135-1 · Cited by 90
Heinemann, A., Cullinane, C. M., Paoli‐Iseppi, R. D., Wilmott, J. S., Gunatilake, D., Madore, J., Strbenac, D., Yang, J. Y. H., Gowrishankar, K., Tiffen, J. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4242 · Cited by 86
Nishiyama, A., Dey, A., Miyazaki, J., & Ozato, K. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-08-0729 · Cited by 85
Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
Borbély, G., Haldosén, L.-A., Dahlman‐Wright, K., & Zhao, C. (2015) · Oncotarget · doi:10.18632/oncotarget.5601 · Cited by 83
Mechanisms of tumor cell resistance to the current targeted-therapy agents
Khamisipour, G., Jadidi‐Niaragh, F., Jahromi, A. S., Zandi, K., & Hojjat‐Farsangi, M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5059-1 · Cited by 79
Clinical progress and pharmacology of small molecule bromodomain inhibitors
Theodoulou, N. H., Tomkinson, N. C. O., Prinjha, R. K., & Humphreys, P. G. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.05.028 · Cited by 76
Regulation of Aurora B Expression by the Bromodomain Protein Brd4
You, J., Li, Q., Wu, C., Kim, J., Ottinger, M., & Howley, P. M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00299-09 · Cited by 73
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
Ball, B. J., Zeidan, A. M., Gore, S. D., & Prébet, T. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1228927 · Cited by 69
Muralidharan, S. V., Bhadury, J., Nilsson, L. M., Green, L. C., McLure, K. G., & Nilsson, J. A. (2016) · Oncogene · doi:10.1038/onc.2015.521 · Cited by 64
Abramson, J. S., Blum, K. A., Flinn, I. W., Gutierrez, M. E., Goy, A. H., Maris, M. B., Cooper, M. R., O’Meara, M., Borger, D. R., Mertz, J. A., et al. (2015) · Blood · doi:10.1182/blood.v126.23.1491.1491 · Cited by 63
Wong, C., Laddha, S. V., Tang, L. H., Vosburgh, E., Levine, A. J., Normant, E., Sandy, P., Harris, C. R., Chan, C. S., & Xu, E. Y. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.396 · Cited by 62
Epigenetics: A primer for clinicians
Paluch, B. E., Naqash, A. R., Brumberger, Z. L., Nemeth, M. J., & Griffiths, E. A. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.02.002 · Cited by 58
Shapiro, G. I., Dowlati, A., LoRusso, P. M., Eder, J. P., Anderson, A., Do, K. T., Kagey, M. H., Sirard, C. A., Bradner, J. E., & Landau, S. B. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-a49 · Cited by 47
Self-citationMolecular Pathways: Targeting the PI3K Pathway in Cancer—BET Inhibitors to the Rescue
Στρατικόπουλος, Η., & Parsons, R. E. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2389 · Cited by 47
BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
Paoluzzi, L., Hanniford, D., Sokolova, E., Osman, I., Darvishian, F., Wang, J., Bradner, J. E., & Hernando, E. (2016) · Cancer Medicine · doi:10.1002/cam4.667 · Cited by 45
Overcoming Resistance to Targeted Therapies in Cancer
Redmond, K. L., Papafili, A., Lawler, M., & Schaeybroeck, S. V. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.028 · Cited by 41
O'Dwyer, P. J., Piha-Paul, S. A., French, C. A., Harward, S., Ferron‐Brady, G., Wu, Y., Barbash, O., Wyce, A., Annan, M., Horner, T., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-ct014 · Cited by 41
Concomitant BET and MAPK blockade for effective treatment of ovarian cancer
Jing, Y., Zhang, Z., Ma, P., An, S.-M., Shen, Y. H., Zhu, L., & Zhuang, G. (2015) · Oncotarget · doi:10.18632/oncotarget.6309 · Cited by 36
Massard, C., Soria, J., Stathis, A., Delord, J., Awada, A. H., Peters, S., Lewin, J. H., Bekradda, M., Rezaï, K., Zeng, Z., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32609-0 · Cited by 30
Postel-Vinay, S. C., Herbschleb, K. H., Massard, C., Woodcock, V. K., Ocker, M., Wilkinson, G., Walter, A. O., Ewerton, F., Poelman, M., Middleton, M. R., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32620-x · Cited by 17
Attwell, S., Jahagirdar, R., Norek, K., Calosing, C., Tsujikawa, L. M., Kharenko, O. A., Patel, R. G., Gesner, E. M., Corey, E., Nguyen, H. M., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-lb-207 · Cited by 8
Koblish, H. K., Hansbury, M., Hall, L. M., Wang, L.-C., Zhang, Y., Covington, M. B., Burn, T. C., Rupar, M. J., Gardiner, C. M., Condamine, T., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-4904 · Cited by 4
Cited by
Targeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
MYC as a target for cancer treatment
Duffy, M. J., O'Grady, S., Tang, M., & Crown, J. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102154 · Cited by 514
Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 445
Lewin, J., Soria, J.-C., Stathis, A., Delord, J.-P., Peters, S., Awada, A., Aftimos, P. G., Bekradda, M., Rezai, K., Zeng, Z., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2292 · Cited by 284
Metadata
- Authors
- Doroshow, D. B., Eder, J. P., & LoRusso, P. M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 28
- Issue
- 8
- Pages
- 1776-1787
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2738383040
- Cited by
- 367
- References
- 89
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.